A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance

Interventions

DRUG

Olutasidenib

Given by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston